Neumora Therapeutics Inc. Common Stock logo

Neumora Therapeutics Inc. Common Stock

NMRA | NASDAQ
Chart Builder DCF Calculator
$0.69
-$0.04 (-5.48%)
At close: Sep 21, 2026, 4:00 PM ET
$0.73
+$0.04 (+5.52%)
Pre-market: Sep 22, 2026, 8:27 AM ET
Fiscal Quarter
Period Ending
Q2 2026
Jun 29, 2026
Q1 2026
Mar 30, 2026
Q4 2025
Dec 30, 2025
Q3 2025
Sep 29, 2025
Q2 2025
Jun 29, 2025
Q1 2025
Mar 30, 2025
Q4 2024
Dec 30, 2024
Q3 2024
Sep 29, 2024
Q2 2024
Jun 29, 2024
Q1 2024
Mar 30, 2024
Q4 2023
Dec 30, 2023
Q3 2023
Sep 29, 2023
Q2 2023
Jun 29, 2023
Q1 2023
Mar 30, 2023
Q4 2022
Dec 30, 2022
Q3 2022
Sep 29, 2022
Q2 2022
Jun 29, 2022
Q1 2022
Mar 30, 2022
Q4 2021
Dec 30, 2021
Q3 2021
Sep 29, 2021
Q2 2021
Jun 29, 2021
Q1 2021
Mar 30, 2021
Revenue
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a 8K n/a 5M n/a n/a n/a n/a n/a n/a 166K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a -8K n/a -5M n/a n/a n/a n/a n/a n/a -166K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Income
-42.19M -52.86M -58.48M -57.7M -54.04M -70.94M -62.92M -76.65M -63.82M -60.07M -50.1M -56.86M -42.06M -39.17M -30.72M -30.6M -31.31M -43.24M -26.55M -178.13M -17.2M -15.45M
Interest Income
935K 1.23M 1.34M 1.69M 1.81M 3.07M 4.09M 4.21M 5.27M 6.37M 5.65M 3.84M 3.56M 3.57M 2.29M 1.41M 784K 86K n/a n/a n/a n/a
Pretax Income
-43.08M -53.43M -59.45M -56.76M -52.71M -67.89M -58.82M -72.49M -58.58M -53.72M -108.46M -53.03M -38.54M -35.63M -28.15M -29.34M -30.37M -43.04M -26.97M -178.03M -17.01M -15.3M
Net Income
-43.08M -53.46M -59.45M -56.76M -52.73M -67.99M -58.82M -72.55M -58.7M -53.72M -108.73M -53.03M -38.54M -35.63M -28.15M -29.34M -30.37M -43.04M -26.97M -178.03M -17.01M -15.3M
Selling & General & Admin
12.91M 14.27M 13.81M 12.18M 15.32M 18.79M 17.01M 16.02M 15.19M 14.32M 11.07M 15.26M 9.29M 9.68M 7.2M 8.05M 7.79M 8.09M 7.64M 6.66M 6.31M 3.94M
Research & Development
29.28M 38.6M 44.67M 40.52M 38.72M 52.15M 45.91M 60.63M 48.63M 45.76M 38.86M 41.6M 32.77M 29.49M 23.52M 22.55M 23.53M 35.15M 18.91M 171.47M 10.89M 11.5M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
42.19M 52.86M 58.48M 52.7M 54.04M 70.94M 62.92M 76.65M 63.82M 60.07M 49.93M 56.86M 42.06M 39.17M 30.72M 30.6M 31.31M 43.24M 26.55M 178.13M 17.2M 15.45M
Interest Expense
1.82M 1.85M 2.04M 747K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
42.19M 52.86M 58.48M 57.7M 54.04M 70.94M 62.92M 76.65M 63.82M 60.07M 50.1M 56.86M 42.06M 39.17M 30.72M 30.6M 31.31M 43.24M 26.55M 178.13M 17.2M 15.45M
Income Tax Expense
n/a 30K n/a n/a 25K 105K n/a 53K 125K n/a 268K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
185.16M 179.87M 163.39M 161.84M 161.69M 161.45M 160.98M 159.58M 158.98M 157.94M 158.83M 155.39M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M
Shares Outstanding (Diluted)
185.16M 179.87M 163.39M 161.84M 161.69M 161.45M 160.98M 159.58M 158.98M 157.94M 158.83M 155.39M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M 151.95M
EPS (Basic)
-0.23 -0.30 -0.35 -0.35 -0.33 -0.42 -0.37 -0.45 -0.37 -0.34 -0.68 -0.34 -0.25 -0.23 -0.19 -0.19 -0.20 -0.28 -0.18 -1.17 -0.11 -0.10
EPS (Diluted)
-0.23 -0.30 -0.35 -0.35 -0.33 -0.42 -0.37 -0.45 -0.37 -0.34 -0.68 -0.34 -0.25 -0.23 -0.19 -0.19 -0.20 -0.28 -0.18 -1.17 -0.11 -0.10
EBITDA
-42.18M -51.57M -57.41M -55.99M -52.69M -67.73M -58.66M -72.34M -58.42M -53.56M -108.3M -52.85M -38.37M -35.47M -28M -29.2M -30.22M -42.9M -26.84M -177.88M -16.89M -15.31M
EBIT
-42.18M -51.57M -57.41M -56.01M -52.71M -67.89M -58.82M -72.49M -58.58M -53.72M -108.46M -53.03M -38.54M -35.63M -28.15M -29.34M -30.37M -43.04M -26.97M -178.03M -17.01M -15.45M
Depreciation & Amortization
n/a 8K 9K 23K 19K 157K 157K 156K 160K 158K 166K 173K 171K 158K 147K 146K 154K 147K 131K 150K 125K 132K

© 2026 bestshares.com. All rights reserved.